Genari AI Briefing Note
Axendia was briefed by Rosalind Beasley, Co-founder and CEO, and Tim Kirkelie, Co-founder and COO, at Genari AI. The company was founded in June 2025 with a focus on compliance and software assurance for the life sciences industry. Genari AI is headquartered in California, with distributed teams across the US, Canada, India, and South Africa.
Beasley’s career spans quality, validation, and compliance innovation in regulated industries. She is the co-founder and co-inventor of 123 Compliance, which was later acquired by Sparta Systems and rebranded as TrackWise Digital. Beasley also serves on the advisory board at Dot Compliance and is a technology insight board member at KENX.
Kirkelie has extensive operational and commercial leadership experience across life sciences. He has led global operations and sales organizations, and launched multiple ERP, CRM, and regulatory compliance solutions at Fortune 100 pharmaceutical and medical device companies. Kirkelie has also led remediation strategies for organizations responding to FDA warning letters.
Built natively on the Salesforce platform, Beasley and Kirkelie position Genari AI at the intersection of compliance, software engineering, and AI governance.
Industry at a Crossroads
During the briefing, Beasley described the life sciences industry as reaching an inflection point. While organizations are rapidly adopting cloud platforms, AI-enabled development tools and automation, many validation practices remain anchored in legacy, document-centric models designed for static systems. “The industry is at a crossroads,” she explained. “Technology is moving at a much faster pace than compliance teams can handle. That’s especially true if they’re still relying on traditional validation models.”
The companies’ vision is to enable life sciences companies to innovate at digital speed without sacrificing quality, safety, or regulatory control. Rather than adapting AI to legacy validation processes, the company is rebuilding assurance from the ground up using a data-centric architecture, layered governance, and agentic AI.
“Our mission is to give regulated organizations provable control, risk-based assurance, and audit-ready evidence as they adopt AI and other modern platforms,” Beasley said
Central to this approach is what Genari AI refers to as a digital validation ledger, where all validation artifacts, including requirements, risks, test cases, execution results, and reports, are stored as structured data rather than static documents.
“We don’t process documents from a validation perspective,” Beasley emphasized. “Everything is data. That data becomes the source of truth for explaining why and how a system is under control.”
GxP Genie and Agentic AI
GxP Genie embeds AI agents directly into the application and validation lifecycle. The platform supports CSA-aligned, risk-based validation activities including risk assessment, test scoping, test case generation, traceability, and validation reporting.
“We ground our agents in real system metadata, pulling from tools such as Jira, GitHub, and GitLab to assess requirements, user stories, and code in context,” explained Beasley.
The platform can integrate with existing ALM tools or be used end-to-end by smaller organizations that lack mature development infrastructure.
Genari AI places a strong emphasis on governance and control of AI agents. Each agent operates within defined guardrails, data access policies, and predefined actions, and must undergo review and approval before production use. Beasley emphasized, “We’re not here to replace people. We’re here to refocus their energy on higher-value, critical thinking activities while the system handles repeatable assurance tasks.”
This approach is particularly relevant for small and mid-sized life sciences organizations seeking AI benefits without increasing inspection exposure.
In Brief
Traditional, document-based validation was designed for static systems, not for AI-driven applications that change, learn, and behave differently depending on context.
As AI-enabled platforms, continuous delivery, and agentic workflows become more prevalent, traditional validation approaches based on static documents and periodic reviews are increasingly misaligned with how systems actually behave in production. This misalignment is particularly acute for organizations experimenting with generative and agentic AI, where system behavior is dynamic, contextual, and data-driven.
Genari AI’s focus on small to mid-sized life sciences organizations addresses a growing gap in the market. While large enterprises are attempting to build internal AI governance and assurance frameworks, most organizations lack the scale, resources, or expertise to do so effectively.
What is changing now is not just the technology, but the evidence model. When an organization’s source of truth is still a document, it is already behind. Data must become the foundation for assurance, traceability, and explainability.
We will continue to provide updates on Genari AI as they become available.
To discuss how this initiative impacts your organization, click on this link to schedule an Analyst Inquiry on this topic.
The opinions and analysis expressed in this post reflect the judgment of Axendia at the time of publication and are subject to change without notice. Information contained in this post is current as of publication date. Information cited is not warranted by Axendia but has been obtained through a valid research methodology. This post is not intended to endorse any company or product and should not be attributed as such.